Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 3220 results found since Jan 2013.
TAX1BP1 contributes to deoxypodophyllotoxin-induced glioma cell parthanatos via inducing nuclear translocation of AIF by activation of mitochondrial respiratory chain complex I
In this study we explored the downstream signal of activated PARP1 to induce nuclear translocation of AIF in DPT-triggered glioma cell parthanatos. We showed that treatment with DPT (450 nM) induced PARP1 over-activation and Tax1 binding protein 1 (TAX1BP1) distribution to mitochondria in human U87, U251 and U118 glioma cells. PARP1 activation promoted TAX1BP1 distribution to mitochondria by depleting nicotinamide adenine dinucleotide (NAD+). Knockdown of TAX1BP1 with siRNA not only inhibited TAX1BP1 accumulation in mitochondria, but also alleviated nuclear translocation of AIF and glioma cell death. We demonstrated that T...
Source: Acta Pharmacologica Sinica - May 15, 2023 Category: Drugs & Pharmacology Authors: Xuan-Zhong Wang Shi-Peng Liang Xi Chen Zhen-Chuan Wang Chen Li Chun-Sheng Feng Shan Lu Chuan He Yu-Bo Wang Guang-Fan Chi Peng-Fei Ge Source Type: research
Recent Advances in Novel Recombinant RNAs for Studying Post-transcriptional Gene Regulation in Drug Metabolism and Disposition
Curr Drug Metab. 2023 Apr 25. doi: 10.2174/1389200224666230425232433. Online ahead of print.ABSTRACTDrug-metabolizing enzymes and transporters are major determinants of the absorption, disposition, metabolism, and excretion (ADME) of drugs, and changes in ADME gene expression or function may alter the pharmacokinetics/pharmacodynamics (PK/PD) and further influence drug safety and therapeutic outcomes. ADME gene functions are controlled by diverse factors, such as gene polymorphism, transcriptional regulation, and co-administered medications. MicroRNAs (miRNAs) are a superfamily of regulatory small noncoding RNAs that are t...
Source: Current Drug Metabolism - May 12, 2023 Category: Drugs & Pharmacology Authors: Mei-Juan Tu Aiming Yu Source Type: research
Nanocarriers for Sirna Delivery Aimed at the Treatment of Melanoma: Systematic Review
CONCLUSION: Such being the case, the development of these systems becomes a non-invasive and promising option for the treatment of melanoma.PMID:37170995 | DOI:10.2174/1567201820666230425234700
Source: Current Drug Delivery - May 12, 2023 Category: Drugs & Pharmacology Authors: Brenda Regina de Araujo Tatielle do Nascimento Ana Paula Dos Santos Matos Vanessa Brand ão de Souza Belmiro Mariana Sato de Souza de Bustamante Monteiro Ralph Santos-Oliveira Eduardo Ricci-Junior Source Type: research
Recent Advances in Novel Recombinant RNAs for Studying Post-transcriptional Gene Regulation in Drug Metabolism and Disposition
Curr Drug Metab. 2023 Apr 25. doi: 10.2174/1389200224666230425232433. Online ahead of print.ABSTRACTDrug-metabolizing enzymes and transporters are major determinants of the absorption, disposition, metabolism, and excretion (ADME) of drugs, and changes in ADME gene expression or function may alter the pharmacokinetics/pharmacodynamics (PK/PD) and further influence drug safety and therapeutic outcomes. ADME gene functions are controlled by diverse factors, such as gene polymorphism, transcriptional regulation, and co-administered medications. MicroRNAs (miRNAs) are a superfamily of regulatory small noncoding RNAs that are t...
Source: Current Drug Metabolism - May 12, 2023 Category: Drugs & Pharmacology Authors: Mei-Juan Tu Aiming Yu Source Type: research
Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases
Drug Discov Today. 2023 May 8:103612. doi: 10.1016/j.drudis.2023.103612. Online ahead of print.ABSTRACTDrugs of unknown mechanisms of action are no longer being developed because we have largely capitalized on our improved understanding of the immunopathogenesis of immune-mediated inflammatory diseases (IMIDs) to develop therapeutic monoclonal antibodies (mAbs) and targeted treatments. These therapies have profoundly revolutionized the care of IMIDs. However, because of the heterogeneity of IMIDs and the redundancy of the targeted molecular pathways, some patients with IMIDs might not respond to a specific targeted drug or...
Source: Drug Discovery Today - May 10, 2023 Category: Drugs & Pharmacology Authors: Renaud Felten Philippe Mertz Eden Sebbag Marc Scherlinger Laurent Arnaud Source Type: research
Lipid nanoparticle-mediated drug delivery to the brain
Adv Drug Deliv Rev. 2023 May 5:114861. doi: 10.1016/j.addr.2023.114861. Online ahead of print.ABSTRACTLipid nanoparticles (LNPs) have revolutionized the field of drug delivery through their applications in siRNA delivery to the liver (Onpattro) and their use in the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines. While LNPs have been extensively studied for the delivery of RNA drugs to muscle and liver targets, their potential to deliver drugs to challenging tissue targets such as the brain remains underexplored. Multiple brain disorders currently lack safe and effective therapies and therefore repurposing LNPs could po...
Source: Advanced Drug Delivery Reviews - May 7, 2023 Category: Drugs & Pharmacology Authors: Purva Khare Sara X Edgecomb Christine M Hamadani Eden E L Tanner Devika S Manickam Source Type: research
LncRNA DANCR deficiency promotes high glucose-induced endothelial to mesenchymal transition in cardiac microvascular cells via the FoxO1/DDAH1/ADMA signaling pathway
This study aims to evaluate underlying mechanisms of ADMA in DCM especially for EndMT under diabetic conditions. A diabetic rat model was induced by streptozotocin (STZ) injection, and human cardiac microvascular endothelial cells (HCMECs) were stimulated with high glucose to induce EndMT. Subsequently, the role of ADMA in EndMT was detected either by exogenous ADMA or by over-expressing dimethylarginine dimethylaminohydrolase 1 (DDAH1, degradation enzyme for ADMA) before high glucose stimulation. Furthermore, the relationships among forkhead box protein O1 (FoxO1), DDAH1 and ADMA were evaluated by FoxO1 over-expression or...
Source: European Journal of Pharmacology - April 28, 2023 Category: Drugs & Pharmacology Authors: Meiting Wu Ting Li Ge Li Bingxuan Niu Tian Wu Li Yan Shiming Wang Shuangyi He Chuyi Huang Weiqiang Tong Niansheng Li Junlin Jiang Source Type: research
Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer
Biochem Pharmacol. 2023 Apr 26:115564. doi: 10.1016/j.bcp.2023.115564. Online ahead of print.ABSTRACTCellular protein synthesis is accelerated in human colorectal cancer (CRC), and high expression of protein synthesis regulators in CRC patients is associated with poor prognosis. Thus, inhibition of protein synthesis may be an effective therapeutic strategy for CRC. We previously demonstrated that the quassinoid bruceantinol (BOL) had antitumor activity against CRC. Herein, potent tumor growth suppression (>80%) and STAT3 inhibition was observed in two different mouse models following BOL administration. Loss of body and...
Source: Biochemical Pharmacology - April 28, 2023 Category: Drugs & Pharmacology Authors: Ning Wei James Burnett Desirae L Crocker Yixian Huang Song Li Peter Wipf Edward Chu John C Schmitz Source Type: research
Periostin acts as a bridge between gestational diabetes mellitus (GDM) and chronic inflammation to modulate insulin resistance by modulating PPAR α/NF-κB/TNF-α signaling pathway
CONCLUSION: POSTN levels were significantly higher in pregnant women with GDM and were associated with chronic inflammation and PPARα expression. POSTN may act as a bridge between GDM and chronic inflammation to modulate insulin resistance by modulating PPARα/NF-κB/TNF-α signaling pathway.PMID:37106515 | DOI:10.2174/1871530323666230427104724
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - April 28, 2023 Category: Drugs & Pharmacology Authors: Qun Ji Xinying Li Yan Wang Haiwei Liu Kaining Chen Huibiao Quan Huachuan Zhang Jianmin Ran Source Type: research
Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer
Biochem Pharmacol. 2023 Apr 26:115564. doi: 10.1016/j.bcp.2023.115564. Online ahead of print.ABSTRACTCellular protein synthesis is accelerated in human colorectal cancer (CRC), and high expression of protein synthesis regulators in CRC patients is associated with poor prognosis. Thus, inhibition of protein synthesis may be an effective therapeutic strategy for CRC. We previously demonstrated that the quassinoid bruceantinol (BOL) had antitumor activity against CRC. Herein, potent tumor growth suppression (>80%) and STAT3 inhibition was observed in two different mouse models following BOL administration. Loss of body and...
Source: Biochemical Pharmacology - April 28, 2023 Category: Drugs & Pharmacology Authors: Ning Wei James Burnett Desirae L Crocker Yixian Huang Song Li Peter Wipf Edward Chu John C Schmitz Source Type: research
